Pancreatic cancer treatment: chemo first, then targeted MRI-guided radiation
Part of Cancer clinical trials.
This Phase 2 trial tests giving specific chemotherapy in sequence, then using MRI-guided focused radiation to treat locally advanced, non-removable pancreatic cancer. It may help shrink or control the tumor while aiming radiation more precisely using MRI.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old
- Your pancreatic cancer diagnosis is confirmed by biopsy or fluid test
- Your cancer is locally advanced but not removable by surgery, and it has not spread to distant organs
- You must be well enough for treatment (ECOG performance status 0–1)
- You need recent blood/organ tests that meet set safety numbers (blood counts, liver, kidneys, electrolytes)
- You’ve never had prior treatment for pancreatic cancer (chemo, radiation, surgery, targeted therapy, or other study drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new, precise form of radiation therapy for locally advanced pancreatic cancer that uses MRI to target the tumor more accurately. It aims to improve treatment effectiveness while reducing damage to surrounding healthy tissue.
This trial tests a special, high-dose radiation treatment for pancreatic cancer that has not spread but cannot be removed with surgery. The goal is to shrink the tumor and improve control of the cancer in the abdomen.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests whether giving a strong, focused dose of radiation can help people with locally advanced pancreatic cancer that has shrunk or stayed stable with first-line chemotherapy. It aims to improve outcomes for those who cannot have surgery.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.